Dudediligence.

Gossamer Bio, Inc

GOSSNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$9.5MSep ’24$9.4MDec ’24$9.9MMar ’25$11.5MJun ’25$13.3MSep ’25$13.8MDec ’25$17.0MMar ’26$9.2MJun ’26
Net income, by quarter
−$30.8MSep ’24−$33.0MDec ’24−$36.6MMar ’25−$38.3MJun ’25−$48.2MSep ’25−$47.2MDec ’25−$46.7MMar ’26$16.9MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on file$0.00$0.00$114.7M$48.5M
Operating income−$216.1M−$218.6M−$183.8M−$59.9M−$170.7M
Net income−$234.0M−$229.4M−$179.8M−$56.5M−$170.4M
Operating cash flow−$188.9M−$187.0M−$159.2M−$3.5M−$171.3M
Free cash flow−$190.4M−$187.4M−$159.2M−$3.5M−$171.3M
Cash$183.4M$112.0M$32.1M$46.1M$37.7M
Debt$29.1M$23.6M$12.4M$0.00none on file
Shares outstanding75.8M94.4M225.4M226.6M233.7M